解锁乳酸在重症患者中的代谢与抗炎治疗潜力
本文综述乳酸生理(生成、转运、跨器官代谢)及外源性乳酸的治疗证据。实验模型和临床研究数据提示,外源性乳酸尤其高渗盐水乳酸(HSL)在脓毒症、急性心力衰竭和脑损伤中改善血流动力学、减少炎症并增强器官功能。乳酸给药在恢复代谢稳态、改善微循环、支持心脏和脑恢复方面显示前景。但重症临床研究仍有限,主要因乳酸多被视为不良预后标志物而非具治疗价值的能量底物。结论认为乳酸治疗代表重症管理范式转变,但需更大规模、设计良好的随机试验确立其安全性、疗效和最佳适应证。
要点
- 实验模型和临床研究数据提示,外源性乳酸尤其高渗盐水乳酸(HSL)在脓毒症、急性心力衰竭和脑损伤中改善血流动力学、减少炎症并增强器官功能。
- 乳酸给药在恢复代谢稳态、改善微循环、支持心脏和脑恢复方面显示前景。
- 重症临床研究仍有限,主要因乳酸多被视为不良预后标志物而非具治疗价值的能量底物。
- 结论认为乳酸治疗代表重症管理范式转变,但需更大规模、设计良好的随机试验确立安全性、疗效和最佳适应证。
- 乳酸的治疗性重定位可能补充或替代ICU当前的复苏液体和代谢调节剂。
适用人群与场景
- 脓毒症、急性心力衰竭和脑损伤的重症患者(基于实验模型和临床研究数据)
研究设计与关键结果
- 综述汇总乳酸生理(生成、转运、跨器官代谢)及外源性乳酸治疗证据,实验模型和临床研究数据提示外源性乳酸尤其高渗盐水乳酸(HSL)在脓毒症、急性心力衰竭和脑损伤中改善血流动力学、减少炎症并增强器官功能。
- 乳酸给药在恢复代谢稳态、改善微循环、支持心脏和脑恢复方面显示前景。
- 重症临床研究仍有限,主要因乳酸多被视为不良预后标志物而非具治疗价值的能量底物。
证据类型、等级与局限
- 证据类型:综述。
- 局限:临床研究仍有限;需更大规模、设计良好的随机试验确立安全性、疗效和最佳适应证。
对床旁实践的改变
- 作者认为乳酸治疗代表重症管理范式转变,可能补充或替代ICU当前的复苏液体和代谢调节剂。
- 作者指出需更大规模、设计良好的随机试验确立乳酸治疗的安全性、疗效和最佳适应证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lactate, traditionally viewed as a biomarker of hypoxia and severity in critical illness, has recently emerged as a potential therapeutic agent. Its roles extend beyond energy metabolism to include anti-inflammatory and signaling functions. This review explores the evolving evidence supporting lactates therapeutic application in critical care settings.
MAIN BODY: We synthesize current knowledge on lactate physiology, including its production, transport, and metabolism across organs. Experimental models and clinical studies data suggest that exogenous lactate, particularly in the form of hypertonic sodium lactate (HSL), improves hemodynamics, reduces inflammation, and enhances organ function in sepsis, acute heart failure, and brain injury. Lactate administration shows promise in restoring metabolic homeostasis, improving microcirculation, and supporting cardiac and cerebral recovery. However, clinical studies in critical care remain limited, largely because lactate is predominantly regarded as a marker of poor prognosis rather than as a potential energy substrate with therapeutic value.
CONCLUSION: Lactate-based therapy represents a paradigm shift in the management of critical illness. While preclinical data are promising, larger, well-designed randomized trials are needed to establish its safety, efficacy, and optimal indications. The therapeutic repositioning of lactate could complement or replace current resuscitation fluids and metabolic modulators in intensive care unit (ICU).
参考来源
- Tchatat Wangueu L, Correia E, Tamion F, et al. Unlocking the metabolic and anti-inflammatory therapeutic potential of lactate in critically ill patients. Crit Care. 2025. PMID: 41137071. doi:10.1186/s13054-025-05665-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。